Auris Medical (NASDAQ:EARS) Downgraded to Strong Sell at Zacks Investment Research

Auris Medical (NASDAQ:EARS) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research note issued on Thursday, Zacks.com reports.

According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. “

EARS stock traded down $0.01 during mid-day trading on Thursday, hitting $2.71. 69,037 shares of the stock were exchanged, compared to its average volume of 155,115. The business has a fifty day moving average price of $2.70 and a 200 day moving average price of $1.85. Auris Medical has a 12 month low of $2.41 and a 12 month high of $39.40. The stock has a market capitalization of $5.07 million, a price-to-earnings ratio of -0.18 and a beta of -0.50.

An institutional investor recently bought a new position in Auris Medical stock. Jane Street Group LLC purchased a new position in shares of Auris Medical Holding Ltd (NASDAQ:EARS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,934 shares of the biotechnology company’s stock, valued at approximately $30,000. Jane Street Group LLC owned about 0.58% of Auris Medical as of its most recent SEC filing. 19.97% of the stock is currently owned by hedge funds and other institutional investors.

Auris Medical Company Profile

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Read More: What is the strike price in options trading?

Get a free copy of the Zacks research report on Auris Medical (EARS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.